Glaxo slides on Avandia woes in U.K.

BOSTON (MarketWatch) -- Shares of GlaxoSmithKline PLC fell 2% to $38.47. According to Reuters, U.K. regulators have recommended removing Glaxo's controversial diabetes drug Avandia from the U.K. market over concerns it can aggravate heart problems in certain users. European regulators are scheduled to review Avandia's safety profile on Sept. 8, with a final decision expected by Sept. 23. Adding ...

More evolution than Eureka!

BaselWorld and the SIHH in Geneva are magnificent showcases of the world’s watch manufacturers. Although we journalists tend to think that they attend for our benefit, the watch companies participate with one objective: to sell ... and 2006 appears to have been a fabulous year.

Bold, black, and brilliant …

This was the year when we saw it all: technical innovations, durable designs, untamed imagination and an amazing surge in sales. Now all that has to be done is deliver the products …

The Buzz: Hawks' trade headache

THE latest footy whispers every day at noon. Today: Which big name can the Hawks offer as trade bait, and all the goss from the AFLPA MVP awards.

'I thought I was going to die. I really did.'

CHRISTCHURCH: The quake turned a modern, relatively prosperous city into a place of curfews, with political leaders flying in and people clamouring for supplies in scenes reminiscent of disasters in less developed parts of the world.